Table 2.
Prevalence of detected mutations in circulating tumor DNA (ctDNA) samples.
| BRAF | EGFR | KRAS | ERBB2 | PIK3CA | Number of Pts | Median VAF | |
|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | with Mutation (%) | of All Mutations | |
| Oligo-brain metastases (n = 20) * | 2 (10.0%) | 2 (10.0%) | 7 (35.0%) | 1 (5.0%) | 0 | 10 (50.0%) | 0.4 |
| Multi-brain metastases (n = 16) ** | 0 | 6 (37.5%) | 2 (12.5%) | 0 | 0 | 7 (43.8%) | 0.9 |
| Other metastases (n = 16) *** | 0 | 4 (25.0%) | 2 (12.5%) | 1 (6.3%) | 2 (12.5%) | 8 (50.0%) | 1.2 |
* Patient P12 had both an EGFR and a KRAS mutation, patient P21 had a KRAS and an ERBB2 mutation. ** Patient P07 had EGFR and KRAS mutations. *** Patient P23 had KRAS and PIK3CA mutations.